Aisle7 promotes health, wellness with online widget gallery
PORTLAND, Ore. Aisle7 on Thursday announced the launch of its Aisle7 online widget gallery, home to plug-and-play mini apps that easily can be placed on a website to inform shoppers of the latest health recommendations, provide shopping ideas and recommend products for health-and-wellness goals. The widgets also provide website content producers a cost-effective solution that automatically updates a page with the latest wellness content without extra development overhead.
“As part of our LiveRight with ShopRite program, we have partnered with Aisle7 to deliver relevant and credible health-and-wellness content and health widgets for our Shoprite.com customers,” stated Cheryl Williams, VP marketing for Wakefern Food Corp. “This helps our customers make informed decisions about health-and-wellness choices for their lifestyle, and provides our customers with a valuable service.”
The new widgets come in the following formats:
- Slideshows — media-rich presentations that engage shoppers with tips and recommendations for top health concerns and goals;
- Product finders — interactive consumer decision tools that connect shoppers with self-care products and improve site conversion; and
- Favorites and indexes — multitabbed content containers that feature the most important wellness recommendations for a health goal.
The widget gallery also includes widgets for campaigns, quick tips and news providing retailers numerous options to build customized landing pages that support a marketing program. Trend-inspired topics, such as diabetes prevention, antiaging and healthy eating, are available in multiple widget types to support an existing page or build a new page from scratch to target a specific audience.
“We’re excited about the new opportunities the widget gallery provides our customers to target their shoppers on the latest wellness topics,” stated Jeffrey Beyer, CEO of Aisle7. “The Aisle7 online widget gallery allows our customers to both drive higher levels of engagement and improve site conversion for their online wellness marketing programs.”
Decision Resources: More patients switch to Onglyza from Merck’s Type 2 diabetes drugs
BURLINGTON, Mass. Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug from Merck’s Januvia (sitagliptin) and Janumet (sitagliptin and metformin), according to a new report by market research firm Decision Resources.
The report found that 9.3% of patients for whom Onglyza –– made by Bristol-Myers Squibb and AstraZeneca –– was not their first Type 2 diabetes drug had previously used Januvia, while 7.9% had used Janumet. All three drugs belong to the same class, known as DPP-IV inhibitors.
“While about half of physicians we surveyed predict their prescribing of Onglyza will increase over the next two years, and Onglyza has picked up some patient share from Januvia and Janumet, Januvia’s more favorable formulary positioning and noncoverage of Onglyza will remain important hurdles for Onglyza’s uptake,” Decision Resources analyst Kate Sullivan said.
NYT article: FSA changes shed light on old eligibility problems
NEW YORK A New York Times report published Tuesday illustrated exactly how far apart the rubber is from the road when it comes to incentivizing preventive healthcare practices and the implementation of the new rules associated with the Patient Protection and Affordable Care Act.
Even as common over-the-counter remedies soon will require a prescription in order to be eligible for reimbursement under flexible spending account arrangements, tried and true preventive healthcare practices, such as breast-feeding, are not and in fact have never been considered eligible for FSA reimbursement, the report noted. “With all the changes the healthcare overhaul will bring in the coming years, it nonetheless will leave those regulations intact when new rules for flexible spending accounts go into effect in January,” the report read.
Breast pumps are not considered eligible FSA expenditures despite the fact that the American Academy of Pediatrics made a direct appeal to the Internal Revenue Service to define such products as breast pumps as a device used for medical care. In May 2009, the IRS determined that breast pumps do not diagnose, cure, mitigate, treat or prevent disease. However, the Food and Drug Administration regulates the manufacture of breast pumps as medical devices, and there are numerous studies that establish the preventive health benefits for children consuming their mother’s breast milk.